PHASE 4 — SCF FIBONACCI STACK DESIGN | AEROVIA-201 / TCP-201 — Localized Neutrophil Elastase Modulation

Phase Code: SCF-CF-AEROVIA201-EBP-P4-0001

Objective: Convert Phase 3 synergy scoring into a structured SCF Fibonacci therapeutic stack for preclinical API development.

4.1 Selected Lead Architecture

Primary scaffold direction:

Taspine-inspired inhaled elastase-injury modulator

Secondary harmonization logic:

Iridoid-inspired cytokine modulation

Pulmonary support logic:

Copaiba terpene-derived anti-inflammatory harmonization

4.2 SCF Fibonacci Stack

Stack Position	Count	Component	Function
F1	1	AEROVIA-201 lead scaffold	Localized neutrophil elastase modulation
F1	1	Iridoid-inspired cytokine harmonizer	IL-8 / TNF / NF-κB tone reduction
F2	2	Nrf2-support module + ECM-preservation module	Redox protection and matrix stabilization
F3	3	DPI carrier + muco-penetrating excipient + lung-retention enhancer	Pulmonary delivery optimization
F5	5	Supportive analog pool	Backup scaffold diversity and safety tuning

4.3 Role Assignment

SCF Role	Assigned Component	Development Intent
Target Modulator	AEROVIA-201 lead scaffold	Reduce elastase-mediated tissue destruction
Safety Harmonizer	Iridoid-inspired harmonizer	Avoid excessive inflammatory suppression
Metabolic Regulator	Nrf2-support module	Reduce ROS-mediated airway injury
Absorption Enhancer	DPI / muco-penetrating delivery system	Improve lung deposition and mucus penetration
Resistance Prevention Support	Supportive analog pool	Reduce pathway compensation and preserve host defense

4.4 Mechanistic Stack Logic

CF airway inflammation
      ↓
Neutrophil recruitment
      ↓
Elastase excess
      ↓
ECM degradation + epithelial injury
      ↓
MMP activation + cytokine amplification
      ↓
Bronchiectasis progression

AEROVIA-201 Stack Intervention:
Elastase modulation
      +
Cytokine harmonization
      +
Redox protection
      +
Pulmonary retention
      ↓
Reduced tissue injury and improved structural preservation

4.5 Candidate Stack Configuration

Component	Proposed Development Form	Preclinical Function
AEROVIA-201	Synthetic small molecule	Primary elastase-injury modulator
IRD-201H	Iridoid-inspired analog	Cytokine harmonization
NRF-201R	Nrf2-support analog	Oxidative injury control
ECM-201P	Matrix-preservation analog	Elastin/collagen protection
DPI-201C	Dry powder inhalation carrier	Lung targeting
MUC-201P	Muco-penetrating excipient	CF mucus penetration
LRT-201E	Lung-retention enhancer	Local exposure optimization

4.6 Stack Optimization Requirements

Requirement	Acceptance Target
Elastase modulation	Demonstrated in enzyme and CF sputum assays
Protease selectivity	Preferential elastase activity over related serine proteases
Cytokine modulation	IL-8 / TNF reduction without immune collapse
ECM preservation	Reduced elastin degradation and MMP-9 activation
Pulmonary PK	High lung/plasma exposure ratio
Safety	No meaningful epithelial cytotoxicity or bronchoreactivity

4.7 Phase 4 Decision

Selected preclinical stack:

AEROVIA-201 + iridoid-inspired harmonizer + redox/ECM support + inhaled muco-penetrating delivery system.

Decision:

PROCEED TO PHASE 5 — REVERSE ENGINEERING & PATHWAY ALIGNMENT

MASTER REGISTRY INDEX

SCF-CF-AEROVIA201-EBP-P4-0001 — SCF Fibonacci Stack Design

SCF-CF-API-201 — AEROVIA-201 Pulmonary Neutrophil Elastase Modulator

SCF-FIB-STACK-0001 — SCF Fibonacci Therapeutic Stack Registry

SCF-SEF-MD-0001 — Synergistic Evaluation Framework

SCF-ETHBIO-WF-0001 — SCF Ethnobioprospecting Workflow